Cytori treats patients in adipose stem cell study for breast reconstruction

By Elaine Rigoli

Tampa, Fla., June 1 - Cytori Therapeutics, Inc. said Thursday that it has treated three patients in a study using adult adipose (fat) derived stem and regenerative cells for breast-reconstruction cancer therapy.

"We believe adipose stem and regenerative cells can have an important impact on the overall treatment of breast cancer patients. If we can successfully use these cells, which are relatively easy to obtain, in conjunction with the patient's own fat tissue to reconstruct their breast after partial mastectomy, it will be a significant step forward for this growing patient population," said Keizo Sugimachi, president of Japan's Kyushu Central Hospital, in a news release.

The investigation is a safety and feasibility study in breast cancer patients who have undergone a partial mastectomy, according to a news release.

The study is expected to enroll up to 20 patients.

In addition to safety, the study will evaluate volume retention as well as other outcomes of reconstructive surgery, the release said.

Preliminary results are expected to be available in the first half of 2007.

San Diego-based Cytori develops proprietary cell-based therapeutics using adult stem and regenerative cells derived from adipose tissue, also known as fat.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.